Background: Short-chain fructooligosaccharides (scFOS) have beneficial effects in subjects with minor digestive complaints, but the potential mechanisms involved have not been elucidated. The aim of the study was to evaluate changes in rectal sensitivity related to the clinical effects of scFOS in a selected group of patients with irritable bowel syndrome (IBS) and rectal hypersensitivity.
| INTRODUCTION
Irritable bowel symptoms have been related to a combination of sensory and motor abnormalities of the gut. 1, 2 The cause of these abnormalities is not known, but several predisposing and triggering factors have been investigated. In particular, recent studies suggest that intestinal microbiota influence gut sensitivity, and may therefore play a part in this context. Indeed, there is evidence from several studies that the intestinal microbiota of IBS patients is altered when compared to healthy controls 3, 4 and differences in microbiota may be related to their sensory dysfunction.
5
Short-chain fructo-oligosaccharides (scFOS) naturally present in onions, bananas or Jerusalem artichokes, are considered to be prebiotic ingredients known to selectively modulate the composition
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes and activity of the intestinal microbiota. [6] [7] [8] In humans, increasing doses of scFOS supplementation of between 2.5 and 10 g d −1 is associated with an increase in fecal bifidobacteria 7 which is generally greater when the initial concentration of bifidobacteria is relatively low. 9, 10 The increase in fecal butyrate following scFOS supplementation is particularly efficient when the initial concentration of butyrate is low.
11
A randomized, double-blind, placebo controlled study performed on healthy subjects presenting mild functional bowel symptoms demonstrated that regular consumption of 5 g d −1 of scFOS reduced the frequency and intensity of digestive symptoms and improved intestinal discomfort and quality of life.
12
We hypothesized that the effect of scFOS on functional IBS-type symptoms is mediated, at least in part, by changes in microbiota and reduce rectal hypersensitivity in patients with IBS. To test this hypothesis, we designed a double-blind, placebo-controlled, parallel and wellpowered study of selected IBS patients with rectal hypersensitivity.
The primary outcome was a reduction in rectal sensitivity; secondary outcomes were improvement of clinical symptoms and changes in fecal microbiota pattern. database. All participants gave written informed consent prior to inclusion in the study.
| MATERIAL AND METHODS

| Patients
| Test products
The scFOS used were produced from sucrose and contained 5% of simple sugars (sucrose, fructose and glucose) and 95% of pure scFOS divided into 37 ± 6% 1-kestose (GF2), 53 ± 6% nystose (GF3), and 10 ± 6% 1F-β-fructofuranosyl nystose (GF4) (Actilight 950P; BeghinMeiji, Marckolsheim, France). The placebo consisted in completely digestible maltodextrins containing the same proportion (5%) of simple sugars (sucrose, fructose, and glucose) (Maldex 120; Tereos Syral, Marckolsheim, France). Both products were administered in identical 2.5 g sachets. The patients were instructed to take two sachets (5 g)
per day diluted in a drink or mixed with solid food over a 28-day period.
| Experimental design and procedures
The parallel, placebo-controlled, randomized, and double-blind study assessed the effects of dietary supplementation (5 g d −1 ) with scFOS vs placebo for 4 weeks on rectal sensitivity (primary outcome), clinical outcomes and composition of fecal microbiota in IBS patients with rectal hypersensitivity (defined as a discomfort threshold ≤44 g; see Rectal sensitivity below). A computer-generated randomization list was balanced between the two treatments in groups of four subjects.
In each group, patient outcomes were measured immediately before and at the end of the treatment period.
| Rectal sensitivity
Rectal sensitivity was assessed by measuring perceived rectal distension. Rectal distension was produced by inflating a rectal bag by means of a computerized air pump (Tensostat, Sicie, Barcelona, Spain) that applied fixed tension levels to the rectal wall. [14] [15] [16] Stepwise rectal distension was produced in 4-g steps every 2 minutes until participants reported discomfort. At the end of each distending step participants were asked to report the sensations perceived during the preceding minute on a scale of 0-6. 17 The discomfort threshold was defined as the lowest wall tension that induced discomfort (perception score ≥5
on the 0-6 scale). This test was performed before (day 0) and at the end of the intervention period (day 28).
Key Points
• Short-chain fructooligosaccharides (scFOS) improve functional digestive complaints. Our aim was to evaluate the effects of scFOS on rectal sensitivity, fecal microbiota and symptoms in patients with irritable bowel syndrome.
• Rectal sensitivity improved with scFOS and placebo alike;
however, scFOS, but not placebo, significantly increased fecal Bifidobacteria and reduced anxiety scores.
• Changes in microbiota induced by scFOS may be particularly beneficial in patients with digestive symptoms and anxiety.
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| Clinical outcomes
Stool form was evaluated at inclusion using the validated Bristol stool chart. 18 Patients were instructed to fill in at home, validated versions in French and Spanish of the Hospital Anxiety Depression (HAD) scale 19 and Severity Scoring System of IBS. 
| Fecal microbiota analysis
Fecal samples from IBS patients were collected at home within the 15 hours preceding each rectal sensitivity test. The patients were instructed to place the sample in a closed plastic box, to add an Anaerocult A ® sachet (Merck, Darmstadt, Germany) to maintain anaerobic conditions, and to store the box below +15°C until the visit.
After opening the Anaerocult A ® sachet, chemical reactions release CO 2 and absorb O 2 to maintain anaerobic conditions but with no contact of the content of the sachet with the fecal sample.
Fecal samples were immediately homogenized and separated into five tubes stored at −80°C in liquid nitrogen for further processing.
The population levels of taxonomic groups of the fecal microbiota previously shown to be affected in IBS gut microbiota 21, 22 or to be modified by FOS administration, 23 were quantified in fecal samples to the fecal mixture and homogenisation in a bead beater for 5 minutes at 1500 rpm (Retsch MM200; Retscg GmbH, Haan, Germany) before DNA extraction. The DNA extracted was then used to amplify regions of 16S rDNA genes with specific primers. Real-time quantitative PCR was performed using the Brilliant SYBR green system (Roche, Manheim, Germany) with specific primers and under the conditions previously described for Eubacteria, 24 Bifidobacteria, 25 Lactobacilli, 26 Enterobacteriacaea, 27 and Roseburia -E. rectale and Faecalibacterium 
| Statistical analysis
Sample size was calculated anticipating a difference in rectal discomfort threshold between scFOS and saline of 4 g; 30 patients per group
were estimated necessary to demonstrate statistical significance with a power of 80% and a significance level of 5%. Considering a possible exclusion of 20% of patients between the intention to treat (ITT) and the per protocol (PP) populations, 36 subjects per group were needed at the start of the study. Statistical analysis was performed on PP population and not on ITT population because there was only a difference of two subjects between the two (one from the scFOS group and one from the placebo group 
| RESULTS
| Demographic data
Nine patients were screened but finally not randomized because they presented normal rectal sensitivity according to the inclusion criteria (see Participants and Experimental design and Procedures above). The
ITT population consisted of 41 subjects in the scFOS group and 38 subjects in the placebo group. Two subjects were excluded from the PP population because they received unauthorized medical treatment (colonic lavage prior to the rectal sensitivity test and antibiotic treatment). The patients were randomly distributed in a harmonious manner ( Fig. 1) between the two centers with slightly more men in Spain than in France (P=.03) but the distribution of patients according to IBS clinical sub-groups was identical between the two treatments groups (Table 1 ) and the two centers.
| Adverse effects
Intake of scFOS was well-tolerated and the number of adverse events was similar in the scFOS (n=18) and placebo (n=21) groups.
F I G U R E 1 Distribution of subjects among intention to treat and per protocol populations
| Rectal sensitivity
Rectal sensitivity (discomfort threshold measured as the lowest wall tension that induced discomfort) before treatment was identical in the two treatment groups (Table 2 ). After 28 days of treatment, there was a significant improvement in rectal sensitivity both in the scFOS group (discomfort threshold increased by +7.0 ± 13.8 g; P=.003 vs basal) and in the placebo group (by +5.9 ± 13.8 g; P=.013 vs basal), and the difference between groups was not statistically significant (P=.565).
However, post hoc analysis showed that the effect of scFOS was more pronounced in constipation-predominant IBS patients (IBS-C) than in other subgroups (i.e. those with diarrhea or alternating bowel habit): in IBS-C the threshold of discomfort at the end of the study tended to be higher in those receiving scFOS than those receiving placebo (P=.051) (Fig. 2) .
| Clinical outcomes
The IBS severity composite score was identical in the two groups prior to treatment (Table 1 ). This score significantly improved after 28 days (P=.001) but with no difference between the scFOS and placebo groups (−68.7 ± 124.4 and −76.2 ± 123.5, respectively; P=.721). In the sub-group of constipated IBS patients, the reduction in severity score was greater for the scFOS than the placebo group, but the difference was not statistically significant (−122.3 ± 157.2 and −38.1± 120.7, respectively; P=.1258). However, the proportion of subjects feeling abdominal distension at the end of treatment in the scFOS group (72%) was significantly lower (P=.001) than at the start of the study, whereas the effect was not significant in the placebo group where 78% still experienced abdominal distension (P=.110) (Fig. 3 ).
Before treatment, anxiety and depression scores were similar in the scFOS and placebo groups (Table 1) . These scores improved after treatment, but the improvement of both the global score and the anxiety score was significantly greater in the scFOS than in the placebo group (Fig. 4) .
| Fecal microbiota
The composition of the subjects' fecal bacterial populations was similar in both groups at inclusion (Table 3) . By the end of the treatment period a significant increase in Bifidobacteria in the scFOSsupplemented group was observed (P<.05) while total anaerobes and most of the other bacterial groups studied were not modified ( 
| DISCUSSION
This study confirms that scFOS intake stimulates the growth of Bifidobacteria and further shows a significant improvement in anxiety scores in IBS patients as compared with placebo. However, their effect on rectal sensitivity depended on clinical subgroup, with a tendency for improvement with respect to placebo only in the subgroup with constipation.
Many studies indicate that the composition of fecal microbiota in IBS patients differs from that of healthy people 21, 29 and appears to be less stable over time. 30, 31 In particular, a reduction in the fecal bifidobacteria population and Bifidobacterium catenulatum was observed in six of eight studies in a review including European and Asian populations. 21, 32 In addition, differences in the fermentation activities of fecal microbiota have been also described in IBS patients, with a shift toward acetate and propionate rather than butyrate production, 33 and this may be pathophysiologically important, because butyrate may be able to lower visceral perception. 34 A functional dysbiosis in IBS-C gut microbiota was recently reported, 21 leading to higher levels of sulfides and less butyrate production compared with healthy subjects.
Furthermore, altered microbiota of IBS-C patients was also shown to play a role in genesis of visceral hypersensitivity observed in IBSgut microbiota associated rats, probably through a specific bacterial metabolite. 22 In our study, the gut microbiota composition of IBS was investigated through molecular quantification of the main bacterial taxa of the population levels. We acknowledge that Next Generation
Sequencing technology, such as mRNA sequencing, could have provided additional information. As previously observed, 7 the intake of 5 g of scFOS per day for 4 weeks in the present study significantly increased the concentration of fecal Bifidobacteria without significant changes in the other microbial populations that were analyzed, and without increasing the total number of anaerobes. It has been shown that the stimulating effect of scFOS on Bifidobacteria is more prominent when the initial level is low 10 but the dose of scFOS used in our study could have not been enough to induce detectable effects.
The symptom severity score in our IBS pool was in the range of moderate to severe, and was identical in both groups of patients prior to treatment. 20 Symptom severity significantly improved after 4 weeks of treatment but with no difference between the scFOS and placebo groups; note that the placebo effect was very strong and this could explain these negative findings. In a previous study on the effect of scFOS on digestive symptoms in healthy subjects, scFOS reduced the frequency of abdominal distension after 4 weeks of supplementation, and this was not observed with placebo, even if the placebo effect was very strong (more than 70% of subjects felt improved intestinal discomfort).
12
For the first time, our study shows that scFOS improves anxietydepression scores in IBS patients, specifically due to a reduction in anxiety. Whereas the depression score evaluated at the beginning of the study was within the normal range (what is considered as "non case"), anxiety scores reached a level of borderline clinical significance (anxiety set above 11). 19 These pretreatment levels could explain the differential effects of scFOS on anxiety (improved) vs depression (no Rectal hypersensitivity has been proposed as an IBS marker. 38, 39 Abdominal pain could be related to hypersensitivity, and indeed, some studies indicate that hypersensitivity to rectal distension in IBS is predicted by symptom severity. 40, 41 In-vitro and animal studies using human fecal microbiota have also revealed an effect of scFOS on other microbial groups, in particular the Eubacterium rectale -Clostridium coccoides group, 23, 42 that included some of the major butyrate-producing species from the human gut. Accordingly, scFOS are known to stimulate the production of short chain fatty acids (SCFA), and in the long-term this stimulation is rather oriented toward butyrate production. 43, 44 Experimental studies showed that rectal instillation of butyrate increased colonic sensitivity in rats. 45 However, in healthy subjects colonic administration of butyrate, at physiologically relevant concentrations, dose-dependently decreased visceral sensitivity. 34 Contrary with our hypothesis, the effect of scFOS on rectal sensitivity in the group of IBS patients as a whole was similar to that of placebo. Our study included only patients with proven rectal hypersensitivity at prescreening and applied state-ofthe-art methodology. Indeed, the tensostat has been shown to be a reliable tool for the evaluation of visceral sensation (detection of hypersensitivity with 95% sensitivity and 72% specificity). 46 The tensostat applies fixed tension levels to the gut wall; since gut perception relays activation of tension receptors, the tensostat standardizes the stimulus regardless of the size or contractile activity of the organ.
15,16
The 5 g dose was shown to be effective in healthy populations with minor digestive disorders, but may be too low for patients fulfilling IBS criteria. Indeed, scFOS stimulates the growth of Bifidobacteria in a dose-dependent manner from 2.5 to 10 g d −1 in humans. 7 Therefore, a dose of between 5 and 10 g d −1 should be considered for future studies with IBS patients.
However, it is interesting to note that the effects of scFOS on digestive symptoms in our study and elsewhere 47 were more prominent in constipated subjects. It was not evaluated in our study but already reported elsewhere that constipated subjects usually present a lower proportion of Roseburia-E rectale in their fecal microbiota in comparison to healthy subjects. 21, 30 It has also been shown by an in vitro fermentation study and in gnotobiotic mice with human fecal slurry, that scFOS stimulate this group of bacteria. 23, 42 However in our study Roseburia-E rectale was not modified by scFOS and, again, it might be related to the low dose tested and could explain the lack of effect on rectal sensitivity.
Our study failed to prove the primary outcome, but still provides useful data suggesting potential beneficial effects of scFOS in IBS, and provides hints for the proper design of studies in terms of sensitive target population (constipation) and effective dose (>5 g d −1 ).
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T A B L E 3 QPCR quantification (log 10 copies of 16S rRNA gene g −1
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